GenEditing - Disruptive Opportunity in Healthcare🏥?

Gene editing involves inserting, deleting or replacing DNA in a cell or organism. The "CRISPR process" offers us an exciting alternative here. The possibility of such gene editing could clear a path for us to be able to cure genetic diseases or prevent them at an early stage.

The possibility to be able to change individual "codes" in our body, in order to be able to recognize thus arising illnesses or other counter sides at an early stage sounds in the first sense madly exciting! However, in order to be able to carry this out, it is essential to make the codes "visible" in order to identify them individually and to be able to recognize with which diseases individual genes are connected. This process is made possible by gene sequencing.

Illumina is a US manufacturer of equipment for genetic engineering. The company offers sequencing and array-based solutions for genetic and genomic analysis. In addition, the acquisition of GRAIL, which is working to offer early detection of up to 50 types of cancer through blood testing, is another exciting field. With Illumina, we have a shovel seller within the industry, which is also a market leader with a market share of around 70%.

In this regard, I see the field of GenEditing as having a very promising future, although it is difficult to see who will ultimately make the big breakthrough. Thus, in my opinion, Illumina offers a super alternative to participate in the market growth as a shovel seller of the preceding analyses.

What is your opinion on gene editing and the opportunities/risks in this field?

🙋🏽‍♂️Wir consider here a complex topic, in which also I am no PROFI! Nevertheless, I find the issue very exciting & accordingly it would be very nice if we can start an input regarding the companies!

☀️ Have a nice weekend

----------

Source: Illumina.com,
doccheck.com,
biospace.com,
stocknews.com,
fool.com,

You can find an exciting & detailed presentation on YouTube at Aktienfieber